A case report of severe acute respiratory syndrome coronavirus-2
infected patient treated with infliximab
Extensive immune response associated inflammation is the major reason
for the pathological outcome of COVID-19 infection. Infliximab is an
anti tumor necrosis factor (anti-TNF) drug that is used to reduce
inflammation through TNF-α inhibition. Inhibition of main inflammatory
cytokine such as TNF-α may has a potential effect in COVID-19 treatment.
Here, we report the clinical outcome associated with Infliximab
treatment in a 65-year-old woman with confirmed COVID-19 infection.
Infliximab therapy was started on day 9th, patient demonstrated clinical
improvement and recovery from COVID-19. Our findings suggest that the
association of TNF-α inhibition and clinical management together
contributes to COVID-19 patient survival.